Fibrocell raises $45 million

Fibrocell Science Inc. (OTCBB:FCSC) raised $45 million in a private placement through the sale of 450 million shares at $0.10 to individual and institutional investors, including Third Security. Barclays; MTS; and John Carris Investments were placement agents. Fibrocell said the financing will help expand the commercial launch of Laviv azficel-T and support its development in additional indications, such as severe restrictive burn scars, vocal cord scarring and acne scars. Last year, Fibrocell launched the injectable autologous cellular therapy in the U.S. to improve the appearance of moderate to severe nasolabial fold wrinkles (smile lines). ...